VAPO News and Press, Vapotherm Inc. From 12/06/22

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering ...

The following slide deck was published by Vapotherm, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Vapotherm, Inc. 2022 Q3 - Results - Earnings Call Presentation

What Are The Best Penny Stocks To Buy Right Now? The 2022 stock market crash has weighed heavily on retail traders. Whether trading penny stocks or stocks over $100, this year has been a tough one to navigate if you’re a “buy and hold” investor. But the outcomes are l...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the day with a breakdown of the biggest pre-market stock movers for Wednesday! Moving stocks are a restructuring plan, public securities offerings, earnin...

2023 Revenue Covenant tied to percentage of Company’s annual operating plan and substantially waived if Company raises $15 million of new funding Liquidity Covenant reduced to $5 Million Option to pay a portion of loan interest “in kind” to provi...

Vapotherm ( NYSE: VAPO ) stock slumped ~45% on Thursday after Q3 results missed estimates and the company cut its FY22 outlook again. Net loss widened to -$26.21M, compared to -$13.57M in Q3 2021. Total net revenue declined -64.4% Y/Y to $13.55M. The company said...

Vapotherm press release ( NYSE: VAPO ): Q3 GAAP EPS of -$0.98 misses by $0.20 . Revenue of $13.5M (-64.6% Y/Y) misses by $3.02M . Fiscal 2022 Outlook For fiscal 2022, the Company expects net revenue to be in the range of $64 million to $66 million vs $73.94...

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced third quarter 2022 financial results. Third Quarter 2022 Summary Total revenue for the third quarter of 2022 was $13.5 million, an increase of 4.4% over the second qua...

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages ...

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages ...